|
|
Volumn 9, Issue 6, 2010, Pages 417-420
|
|
Evolving R and D for emerging markets
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DAPAGLIFLOZIN;
GEFITINIB;
SAXAGLIPTIN;
SITAGLIPTIN;
ADVANCED CANCER;
ASIA;
CLINICAL TRIAL;
DIABETES MELLITUS;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
HEALTH CARE ACCESS;
HEALTH CARE NEED;
HUMAN;
INCIDENCE;
LIFESTYLE;
LUNG NON SMALL CELL CANCER;
MALIGNANT NEOPLASTIC DISEASE;
MORBIDITY;
MORTALITY;
PREVALENCE;
PRIORITY JOURNAL;
SHORT SURVEY;
ASIA;
COMMERCE;
DRUG DISCOVERY;
DRUG INDUSTRY;
HUMANS;
LIFE STYLE;
|
|
EID: 77953160866
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3204 Document Type: Short Survey |
|
Times cited : (18)
|
|
References (0)
|